Sukumar Nagendran - 14 Dec 2023 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role: President and Head of R&D, Director
Signature: /s/ Kamran Alam, Attorney-in-Fact
Issuer symbol: TSHA
Transactions as of: 14 Dec 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Dec 2023, 16:47:23 UTC
Previous filing: 08 Jun 2023
Next filing: 04 Jan 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TSHA	Employee Stock Option (right to buy)	Award	$0	+334,005		$0.000000	334,005	14 Dec 2023	Common Stock	334,005	$0.6989	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Content

The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.